Scientists record breakthrough in HIV, vaccine

Scientist are working hard in finding cure to HIV,

lets say a cure is found, then there will be no need for condom naa!

because guys now, the only thing wey de fear some guys na STD and if cure dey, Rape go boku die.

but make e for no lost, dem never too sure, its just a study, so still dey use condom guy!

in a press release, it stated:

The experimental regimens tested in this study are based on ‘mosaic’ vaccines that take pieces of different HIV viruses and combine them to elicit immune responses against a wide variety of HIV strains.
Led Researcher, Professor of Medicine, Harvard Medical School, Boston, and Director of the Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Centre, Dan Barouch said: “These results represent an important milestone.
This study demonstrates that the mosaic Ad26 prime, Ad26 plus gp140 boost HIV vaccine candidate induced robust immune responses in humans and monkeys with comparable magnitude, kinetics, phenotype, and durability and also provided 67per cent protection against viral challenge in monkeys.”
He added: “These results should be interpreted cautiously.
The challenges in the development of an HIV vaccine are unprecedented, and the ability to induce HIV-specific immune responses does not necessarily indicate that a vaccine will protect humans from HIV infection.
We eagerly await the results of the phase 2b efficacy trial called HVTN705, or ‘Imbokodo’, which will determine whether or not this vaccine will protect humans against acquiring HIV.”
Almost 37 million people worldwide are living with HIV/AIDS, with an estimated 1.8 million new cases every year. A safe and effective preventative vaccine is urgently needed to curb the HIV pandemic.
In the 35 years of the HIV epidemic, only four HIV vaccine concepts have been tested in humans, and only one has provided evidence of protection in an efficacy trial — a canarypox vector prime, gp120 boost vaccine regimen tested in the RV144 trial in Thailand lowered the rate of human infection by 31% but the effect was considered too low to advance the vaccine to common use.
A key hurdle to HIV vaccine development has been the lack of direct comparability between clinical trials and preclinical studies.
To address these methodological issues, Barouch and colleagues evaluated the leading mosaic adenovirus serotype 26 (Ad26)-based HIV-1 vaccine candidates in parallel clinical and pre-clinical studies to identify the optimal HIV vaccine regimen to advance into clinical efficacy trials.
The APPROACH trial recruited 393 healthy, HIV-uninfected adults (aged 18-50 years) from 12 clinics in east Africa, South Africa, Thailand, and the USA between February 2015 and October 2015.

Guys let me hear your view in the comment section